z-logo
Premium
Exosomes from adipose‐derived stem cells ameliorate phenotype of Huntington's disease in vitro model
Author(s) -
Lee Mijung,
Liu Tian,
Im Wooseok,
Kim Manho
Publication year - 2016
Publication title -
european journal of neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.346
H-Index - 206
eISSN - 1460-9568
pISSN - 0953-816X
DOI - 10.1111/ejn.13275
Subject(s) - microvesicles , huntingtin , huntington's disease , paracrine signalling , biology , microbiology and biotechnology , microvesicle , huntingtin protein , stem cell , apoptosis , western blot , phenotype , cancer research , microrna , medicine , pathology , disease , genetics , gene , receptor
Huntington's disease ( HD ) is a hereditary neurodegenerative disorder caused by the aggregation of mutant Huntingtin ( mH tt). Adipose‐derived stem cells ( ASC s) have a potential for use in the treatment of incurable disorders, including HD . ASC s secrete various neurotrophic factors and microvesicles, and modulate hostile microenvironments affected by disease through paracrine mechanisms. Exosomes are small vesicles that transport nucleic acid and protein between cells. Here, we investigated the therapeutic role of exosomes from ASC s ( ASC ‐exo) using in vitro HD model by examining pathological phenotypes of this model. Immunocytochemistry result showed that ASC ‐exo significantly decreases mH tt aggregates in R6/2 mice‐derived neuronal cells. Western blot result further confirmed the reduction in mH tt aggregates level by ASC ‐exo treatment. ASC ‐exo up‐regulates PGC ‐1, phospho‐ CREB and ameliorates abnormal apoptotic protein level in an in vitro HD model. In addition, Mito SOX Red, JC ‐1 and cell viability assay showed that ASC ‐exo reduces mitochondrial dysfunction and cell apoptosis of in vitro HD model. These findings suggest that ASC ‐exo has a therapeutic potential for treating HD by modulating representative cellular phenotypes of HD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here